PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: SignaBlok, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SignaBlok Wins $1.34M NIH Phase II Grant to Advance New Nanotechnology for Atherosclerosis Imaging - SignaBlok, Inc. was awarded a new NIH SBIR Phase II grant totaling $1.34 million for continuing development of multifunctional nanoformulations for targeted non-invasive detection of vulnerable (high-risk) atherosclerotic plaques - SignaBlok.com
SignaBlok Wins $1.34M NIH Phase II Grant to Advance New Nanotechnology for Atherosclerosis Imaging

 

NewswireToday - /newswire/ - Shrewsbury, MA, United States, 2014/07/29 - SignaBlok, Inc. was awarded a new NIH SBIR Phase II grant totaling $1.34 million for continuing development of multifunctional nanoformulations for targeted non-invasive detection of vulnerable (high-risk) atherosclerotic plaques - SignaBlok.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

SignaBlok, Inc., a Massachusetts-based emerging biopharmaceutical company, announced today the award of a Phase II Small Business Innovation Research (SBIR) grant by the National Heart Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). This project, entitled “Multifunctional nanoformulations for diagnostic imaging of atherosclerosis”, continues the work previously supported by a successfully completed Phase I SBIR grant on the use of SignaBlok’s targeted nanoparticles as a safe and efficient delivery platform for imaging of the most dangerous type of arterial plaques called vulnerable plaques in early diagnosis and treatment of atherosclerosis. This research is a collaborative effort between SignaBlok and the Advanced Magnetic Resonance Imaging (MRI) Center at the University of Massachusetts Medical School, Worcester.

SignaBlok’s proprietary nanosystem for delivery of drugs and imaging agents targets macrophages, inflammatory cells that are critically involved in plaque formation and have a high discriminatory power to identify the vulnerable plaque. The goal of this grant is to advance preclinical studies of new macrophage-targeted MRI imaging agents towards an investigational new drug (IND) application to the FDA.

Alexander Sigalov, Ph.D., President and Founder of SignaBlok said,“We have strong pre-clinical efficacy data that show an MRI contrast agent, when delivered to macrophages by SignaBlok's nanoparticles, significantly improves atherosclerotic plaque detection in an animal model of the disease. This Phase II award will allow us to continue development of our lead candidates. New imaging technique would fill an important unmet need in the diagnosis and treatment of atherosclerosis and offer better way to identify high-risk individuals, provide earlier diagnosis before symptoms occur and monitor treatment effects.”

“Macrophages are important imaging targets for diagnosis and image-guided therapy of not only atherosclerosis but also cancer. Thus, this grant gives us an opportunity to develop targeted nanosystem for in vivo macrophage imaging with a wide range of clinical applications. We are extremely pleased to continue to receive funding from the NHLBI,” said Alexander Sigalov.

Reference: Sigalov AB. Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages. Contrast Media & Mol Imaging, 2014, in press (ncbi.nlm.nih.gov/pubmed/24729189).

About atherosclerosis: Atherosclerosis (hardening of the arteries) is the major cause of cardiovascular disease, the number one leading cause of death worldwide. A vast majority of cardiovascular events such as stroke or myocardial infarction result from rupture or erosion of vulnerable plaques. Accurate in vivo tracking of plaque vulnerability and progression using non-invasive imaging approaches allows early identification of high-risk patients as well as facilitates early intervention decision-making process and monitoring of the effectiveness of interventions.

About SignaBlok
SignaBlok (signablok.com) is developing a new class of therapies SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SignaBlok, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SignaBlok Wins $1.34M NIH Phase II Grant to Advance New Nanotechnology for Atherosclerosis Imaging

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Alexander Sigalov - SignaBlok.com 
203-505-3807 sigalov[.]signablok.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SignaBlok, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SignaBlok, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
Ipsen Announces MHRA Approval of New Indication for Decapeptyl® for the Treatment of Pre-menopausal Women with Early Stage Breast Cancer
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)